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ABSTRACT: Analyzing the type and frequency of patient-
specific mutations that give rise to Duchenne muscular
dystrophy (DMD) is an invaluable tool for diagnostics,
basic scientific research, trial planning, and improved
clinical care. Locus-specific databases allow for the col-
lection, organization, storage, and analysis of genetic
variants of disease. Here, we describe the develop-
ment and analysis of the TREAT-NMD DMD Global
database (http://umd.be/TREAT_DMD/). We analyzed
genetic data for 7,149 DMD mutations held within the
database. A total of 5,682 large mutations were observed
(80% of total mutations), of which 4,894 (86%) were
deletions (1 exon or larger) and 784 (14%) were duplica-
tions (1 exon or larger). There were 1,445 small mutations
(smaller than 1 exon, 20% of all mutations), of which 358
(25%) were small deletions and 132 (9%) small insertions
and 199 (14%) affected the splice sites. Point mutations
totalled 756 (52% of small mutations) with 726 (50%)
nonsense mutations and 30 (2%) missense mutations. Fi-
nally, 22 (0.3%) mid-intronic mutations were observed.
In addition, mutations were identified within the database
that would potentially benefit from novel genetic thera-
pies for DMD including stop codon read-through thera-
pies (10% of total mutations) and exon skipping therapy
(80% of deletions and 55% of total mutations).
Hum Mutat 36:395–402, 2015. Published 2015 Wiley Periodi-
cals, Inc.∗
KEY WORDS: DMD; Duchenne muscular dystrophy;
TREAT-NMD; rare disease registries
Introduction
Duchennemuscular dystrophy (DMD) is a severe, X-linked, pro-
gressive neuromuscular disease caused by mutations in the DMD
gene (DMD; MIM #310200) [Hoffman et al., 1988]. Mutations in
this gene give rise to two forms of muscular dystrophy depending
on whether the translational reading frame is lost or maintained:
severe DMD, due to out of frame mutations leading to loss of pro-
tein function, or a milder form of muscular dystrophy known as
Becker muscular dystrophy (BMD; MIM #300376), caused by a re-
duction in the amount and/or size of dystrophin protein due to
frame maintaining mutations [Koenig et al., 1989]. The DMD gene
is the largest known gene in humans, spanning 2.3 Mb of genomic
DNA. The coding sequence spans 11 Kb and is made up of 79 ex-
ons [Ahn and Kunkel, 1993]. Many different types of mutation have
been described forDMD including large deletions and duplications,
point mutations, and small rearrangements.
DMD has a prevalence of 21.2/100,000 school aged boys [Mah
et al., 2014]. Current care recommendations (specifically, the use of
corticosteroids, cardiac medications, and assisted ventilation) im-
prove outcomes and quality of life but do notmodify the underlying
progression of the disease [Sejerson and Bushby, 2009; Hoffman
et al., 2012]. Potential treatment strategies center primarily on tar-
geted mitigation of the causative genetic mutation. One example
of a genetic-based potential therapy is nonsense stop codon read-
through therapy [Howard et al., 2000; Wagner et al., 2001; Hirawat
et al., 2007; Welch et al., 2007]. These treatments include aminogly-
cosides and ataluren (previously PTC124), and work by selectively
inducing ribosomal read-through of premature stop codons but
not normal stop codons. Specific nonsense mutations exist in DMD
patients leading to premature stop codons (TGA, TAG, and TAA)
and would potentially benefit from this therapy. Translarna recently
obtained conditional marketing authorization from the European
Medicine Agency for use in ambulant Duchenne patients over 5
years of age, and as such is the first drug to be approved for DMD.
A further example is the exon skipping approach. Exon skip-
ping aims to moderate disease progression by taking advantage of
the knowledge that internally deleted dystrophins (seen in BMD)
can be partially functional [Be´roud et al., 2007; Aartsma-Rus et al.,
2009; vanOmmen andAartsma-Rus, 2013]. Significant research has
been undertaken in the field of exon skipping to restore the open
reading frame of dystrophin transcripts resulting in the production
of partly functional dystrophin protein [van Ommen et al., 2008;
Aartsma-Rus et al., 2009]. Exon skipping is achieved by the use of
antisense oligonucleotides (AONs) that specifically bind to and hide
exons from the splicing machinery, leading to an in-frame mRNA
without this exon and giving rise to internally deleted dystrophin
proteins as seen in BMD patients [Takeshima et al., 2001; Aartsma-
Rus et al., 2003, 2004; Surono et al., 2004; McClorey et al., 2006;
Arechavala-Gomeza et al., 2007; Gurvich et al., 2008]. Since DMD
has a relatively high rate of new mutations (one in three mutations
is new), most patients have unique mutations [Aartsma-Rus et al.,
2006; Tuffery-Giraud et al., 2009]. However, approximately 60%–
65% of all DMD patients carry a deletion of one or more exons,
with a tendency to cluster between exons 45 and 55 [Aartsma-Rus
et al., 2006; Tuffery-Giraud et al., 2009]. Furthermore, while the
location of the breakpoints in introns will differ for patients with
a deletion of exon 48–50, these deletions will give rise to identi-
cal transcripts. Therefore, the skipping of certain exons would be
applied to relatively large numbers of patients.
Understanding the type and frequency of patient-specific mu-
tations that give rise to DMD-associated phenotypes is an in-
valuable tool for genetic diagnosis, basic scientific research, and
improved clinical care, potentially leading to new treatments for
the disease. Currently, the TREAT-NMD DMD Global database
contains over 7,000 (7,149 as of November 2013) mutations
(http://umd.be/TREAT_DMD/). Locus-specific databases (LSDBs)
allow for the collection, organization, storage, and analysis of genetic
variants of disease. LSDBs collect all published andunpublishedmu-
tations for a specific gene along with complete clinical and pheno-
typic information.Additional confidence exists in these data sets due
in part to the role of experts or “curators.” Curators validate the data
heldwithin the database and significantly reduce error rates [Be´roud
et al., 2005; Cotton et al., 2008]. In the case of LSDBs for DMD, a
number of databases exist including, the Leidenmuscular dystrophy
pages (http://www.dmd.nl/) in the Netherlands [Aartsma-Rus et al.,
2006], and the UMD-DMD (http://www.umd.be/DMD/) in France
[Cotton et al., 2008].We here report a new globalmutation database
for DMD, and outline how this can be used for genetic analysis and
development of genetic therapies.
Methods
A new global database for DMD (TREAT-NMD DMD Global
database) based on the French UMD-DMD system has been devel-
oped with TREAT-NMD collaboration. TREAT-NMD was initially
established as an EU-funded “network of excellence” with the re-
mit of “reshaping the research environment” in the neuromuscu-
lar field ([http://www.treat-nmd.eu/], 2013; Bushby et al., 2009).
Standardized mutation (DMD mutations) specific data based on
TREAT-NMD mandatory and highly encouraged items from the
national TREAT-NMD DMD registries [Bladen et al., 2013] were
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Figure 1. Upload of data from national TREAT-NMD DMD registries to Global database. Standardized aggregate data from the national TREAT-
NMD DMD registries was transferred to the global DMD database via a secure File Transfer Protocol transfer in order to provide a single cohort
of genetic and clinical variants.
Table 1. Type and Frequency ofMutations Heldwithin the TREAT-
NMD DMD Global Database
Total 7,149
Percentage of
total mutations
Large mutations 5,682 79
Large deletions ( 1 exon) 4,894 68
Large duplications ( 1 exon) 784 11
Small mutations 1,445 20
Small deletions (<1 exon) 358 5
Small insertions (<1 exon) 132 2
Splice sites (<10 bp from exon) 199 3
Point mutations 756 11
Nonsense 726 10
Missense 30 0.4
Mid-intronic mutations 22 0.3
transferred to the global DMD database via a secure File Transfer
Protocol transfer in November 2013 in order to provide a single
cohort of genetic and clinical variants (Fig. 1). Analysis of DMD ge-
netic mutations was then carried out for the 7,149 patient data sets
held within the TREAT-NMD DMD Global database. HGVS (Hu-
manGenomeVariationSociety)nomenclaturewasused throughout
(http://www.hgvs.org/mutnomen/).
Results
The TREAT-NMD DMD Global database currently contains
7,149 DMD mutations. There were 5,684 large mutations (80%),
of which 4,894 (86%) were deletions (1 exon or larger) and 784
(14%) were duplications (1 exon or larger) (Table 1). There were
1,445 small mutations (20% of all mutations), of which 358 (25%)
were deletions (smaller than 1 exon) and 132 (9%) were duplica-
tions (smaller than one exon); 199 (14%) splice site mutations were
recorded. Point mutations totalled 756 (10% of all mutations, 52%
of small mutations) with 726 nonsensemutations (10% of all muta-
tions, 50% of small mutations) and three missense mutations (<1%
of all mutations, 2% of small mutations). Finally, 22 (less than 1%
of all mutations, 0.3% of small mutations) mid-intronic mutations
were observed (Table 1).
Large Mutations
Large deletions
Four thousand eight hundred ninety four large deletions were
reported and accounted for 68% of total mutations. Figure 2a high-
lights the ten most commonly reported (observed more than 100
times) large deletions within the database. The most common large
deletion was a deletion of exon 45, which was recorded 316 times in
the database (4% of deletions). Distribution of large deletions was
nonrandom with the majority of large deletions (80%) covering
either the distal region mutation hot spot of the dystrophin gene
(exons 45–55) or the proximal region (exons 2–20) (Fig. 3).
Large duplications
Seven hundred eighty four large duplications were reported and
accounted for 11% of total mutations. Figure 2b shows the eight
most commonly reported large duplications (observed more than
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Figure 2. Most commonly reported large mutations. Most commonly reported large deletions (recorded 100 times or more) (A) and large
duplications (recorded ten times or more) (B) in the TREAT-NMD DMD Global database.
ten times). The most common large duplication was duplication
of exon 2 (11% of duplications). Distribution of large duplications
was nonrandom with most large duplications involving distal or
proximal mutation hot spots (65%) (Fig. 3).
Single exon deletions and duplications
The five most frequent single exon deletions recorded in the
database (all reported more than 100 times) were deletion of exon
45 (4%), 51 (3%), 44 (3%), 52 (3%), and 50 (2%). Single exon
duplications occurred less frequently than single exon deletions.
Duplication of exon 2 was the most frequent and was reported
50 times, while the second most frequent single exon duplication
was duplication of exon 17 and was reported 11 times in the
database.
Small Mutations
The database contained 1,445 small lesions and included dele-
tions (smaller than 1 exon; 355, 25%), duplications (smaller than
one exon; 132, 9%), 199 (14%) splice site mutations and 756 (52%)
point mutations, 726 (50%) nonsense mutations, 30 (2%)missense
mutations, and 22 (0.3%) mid-intronic mutations (Table 1). Small
deletions and mutations ranged in size from two nucleotides (oc-
curring 85 times) to 111 nucleotides (occurring twice).
Nonsense mutations
Nonsense mutations represented 50% of the small mutations in
the database and 10% of total mutations. Transition mutational
events (70%) were more common than transversions (30%), with
the C-to-T substitution being the most frequent (90%).
Potential DMD therapies
Nonsense stop codon read-through therapy has obtained condi-
tional marketing authorization [Howard et al., 2000; Wagner et al.,
2001; Hirawat et al., 2007; Welch et al., 2007]. This treatment
selectively induces ribosomal read-through of premature stop
codons but not normal stop codons. Mutations were identified
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Table 2. Overview of DMD Exons
Reala Mutation (%) Deletion (%) Adjustedb Mutation (%) Deletion (%)
Exon 51 14.0 20.50 Exon 51 14.0 20.5
Exon 53 10.1 14.7 Exon 45 9.0 13.1
Exon 45 9.0 13.1 Exon 53 8.1 11.8
Exon 44 7.1 11.1 Exon 44 7.6 11.1
Exon 43 7.5 11.0 Exon 50 3.8 5.6
Exon 46 4.6 6.7 Exon 43 3.1 4.5
Exon 50 3.8 5.6 Exon 8 2.00 2.9
Exon 52 3.6 5.3 Exon 55 1.7 2.5
Exon 55 2.7 3.9 Exon 52 0.9 1.3
Exon 8 2.0 2.9 Exon 11 0.9 1.3
aOverview of exons for which single exon skipping would be applicable to the largest
groups of patients.
bAdjusted overview of applicability of single exon skipping.
within the database that would potentially benefit from this ther-
apy. These included 317mutations (4% of overall mutations) with a
premature TGA stop codon, 215 (3%) with a TAG stop codon, and
194 (3%) with a TAA stop codon.
Exon skipping technology takes advantage of the fact that inter-
nally deleted dystrophins, often seen in BMD, can be partially func-
tional. Mutations were identified within the database that would
potentially benefit from exon skipping therapy. The top ten exon
skips that would be applicable to the largest group of patients
were skipping of exon 51 (14% of total mutations/21% of dele-
tions), 53 (10%/15%), 45 (9%/13%), 44 (7%/11%),43 (7%/11%),
46(5%/7%), 50(4%/6%), 52(4%/5%), 55(3%/4%), and 8(2%/3%),
respectively, as shown in Table 2. It is important to point out that the
applicability of exon skipping of certain exons reduces once AONs
targeting other exons have been developed. For example, the reading
frame of exon 52 deletions can be restored by skipping exon 51 or
by skipping exon 53. However, once an AON for exon 51 has been
developed and approved for clinical use, the additional applicability
of exon 53 skipping is then lower than the a priori applicability, since
it now only applies to 8% of mutations rather than 10%, because
the exon 52 deletion has already been rescued by exon 51 skipping.
The top 10 of exon skips and their added applicability (i.e., taking
this adjustment into account) is shown in Table 2.
CpG sites
Substitutions involving a CpG dinucleotide accounted for 31%
(233/756) of point mutations within the database. The CpG din-
ucleotide has been shown to undergo oxidative deamination of 5-
methyl cytosine resulting in a mutational “hot spot” and mutation
rates an order of magnitude higher than normally expected [Akalin
et al., 1994; Krawczak et al., 1998; Flanigan et al., 2009].
Geography and DMD mutations
Regardless of geographical location (determined by continent),
large deletions were by far the most commonly observed (64% in
Oceania to 88% in Africa) mutation followed by large duplications
(5% in Africa to 12% in Europe). The number of small mutations
was generally more variable (7% in Africa to 22% in Oceania) but
this variability is likely explained by the fact that not all countries
routinely assay for point mutations and other small lesions and
indeed numbers of patients were significantly smaller, for example,
in Africa compared to Europe (Fig. 4).
Discussion
Databases
Resources existed for DMD prior to the creation of the TREAT-
NMD DMD Global database, the Leiden muscular dystrophy
pages (http://www.dmd.nl/) in the Netherlands [Aartsma-Rus et al.,
2006], and the UMD-DMD (http://www.umd.be/DMD/) in France
[Cotton et al., 2008]. For both the previously existing databases,
bias of recorded mutations has been an inherent problem due in
part to the method used to determine the mutation. Historically,
detection of deletions and duplications was easier than detection
of point mutations and other small rearrangements leading to an
overrepresentation of such mutations in the literature and indeed
a possible underrepresentation of point mutations and other small
rearrangements. However, this bias is becoming less of an issue due
to current diagnostic techniques that are widely available [Prior and
Bridgeman, 2005; Flanigan et al., 2009]. Also, while initially, the
most commonly occurring mutations were recorded; now there is
potentially a bias toward only novel mutations being recorded in
the Leiden database. In addition to this, the UMD-DMDdatabase is
specific to France and could potentially include a bias for mutations
observed with higher or lower frequencies only in France. The new
TREAT-NMD DMD Global database houses what we believe to be
the single largest cohort of verified DMD mutations in the world
and was established to collect and compare and molecular muta-
tions found within this patient group. Mutational analysis of the
database illustrates the allelic heterogeneity of the DMD gene. In-
deed, one-third of all DMDmutations occur de novo [Laing, 1993].
Analysis and Comparisons
Analysis of the TREAT-NMDDMDGlobal database revealed that
large deletions were the most prevalent genetic mutation recorded
and accounted for 68% of the total mutations analyzed, deletion of
exon 45 being the single most common large deletion (reported 316
times). These results are similar to both the French UMD database
[Tuffery-Giraud et al., 2009] with 62% of the mutations being large
deletions and the Leiden database [Aartsma-Rus et al., 2006], where
72% of the mutations are large deletions. In the Leiden database
and the TREAT-NMD DMD Global databases, deletion of exon 45
was the most common deletion, making up 4% of the mutations
in the TREAT-NMD DMD Global database and 2% of the Leiden
database. Large duplications accounted for 11% of mutations in
the TREAT-NMD DMD Global database compared to 13% in the
French UMD database and 8% in the Leiden database. The most
commonly occurring large duplication was duplication of exon 2
in all three databases. Small rearrangements accounted for 20%
of the TREAT-NMD DMD Global database that was similar to
the French UMD database (26%) and the Leiden database (20%).
Point mutations and nonsense mutation were the most prevalent
small rearrangements with nonsensemutations accounting for 50%
of the small rearrangements in the TREAT-NMD DMD Global
database, compared to 40% in the French UMD database and 50%
in the Leiden database. Large deletions and duplications follow a
nonrandom distribution with 78% of them including either the
proximal or distal mutation hot spots [Koenig et al., 1989; Prior and
Bridgeman, 2005; Aartsma-Rus et al., 2006].
Reading Frame Rule
The majority of the reported (DMD) mutations in the TREAT-
NMD DMD Global database resulted in frame-shift mutations
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Figure 3. Distribution of the most common large deletions and duplications on the DMD gene.
Figure 4. Geography and DMD mutations. Distribution of DMD mutation types stratified by continent.
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(93%). Mutations not following the reading-frame rule in the
TREAT-NMD DMD Global database accounted for 7% of total
mutations compared with 4% in the UMD-DMD database and 9%
in the Leiden database.
Potential DMD Therapies
Several potential novel DMD therapies exist and are focused
on the mitigation of the underlying genetic defect. The two most
promising examples are nonsense read-through and exon skipping.
Mutationswere identifiedwithin the database thatwouldpotentially
benefit from this stop codon read-through therapy (10% of muta-
tions). Exon skippingmutations were identified within the database
that would potentially benefit from exon skipping therapy (55% of
total mutations and 80% of deletions).
Understanding the type and frequency of patient-specific muta-
tions that give rise to DMD-associated phenotypes will potentially
lead to personalized (targeted/precision) therapies.DMDessentially
serves as a paradigm for this type of treatment and ultimately could
lead the way to similar approaches in other rare diseases and indeed
in more common disorders.
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